Abstract
Three years after the introduction of natalizumab (NA) therapy for the second line treatment of relapsing-remitting multiple sclerosis (MS), Italian MS centers critically reviewed the scientific literature and their own clinical experience. Natalizumab was shown to be highly efficaciuos in the treatment of MS. However, the risk of progressive multifocal leukoencephalopathy was confirmed and defined better. This article summarizes the MS-SIN Study Group recommendations on the use of NA in MS, with particular reference to the appropriate selection and monitoring of patients as well as to the management of adverse events.
| Original language | English |
|---|---|
| Pages (from-to) | 351-358 |
| Number of pages | 8 |
| Journal | Neurological Sciences |
| Volume | 32 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Apr 2011 |
Fingerprint
Keywords
- IRIS
- Multiple sclerosis
- Natalizumab
- PML
ASJC Scopus subject areas
- Clinical Neurology
- Psychiatry and Mental health
- Dermatology
Cite this
Natalizumab therapy of multiple sclerosis : Recommendations of the Multiple Sclerosis Study Group-Italian Neurological Society. / Ghezzi, A.; Grimaldi, L. M E; Marrosu, M. G.; Pozzilli, C.; Comi, G.; Bertolotto, A.; Trojano, M.; Gallo, P.; Capra, R.; Centonze, D.; Millefiorini, E.; Sotgiu, S.; Brescia Morra, V.; Amato, M. P.; Lugaresi, A.; Mancardi, G.; Caputo, D.; Montanari, E.; Provinciali, L.; Durelli, L.; Bergamaschi, R.; Bellantonio, P.; Tola, M. R.; Cottone, S.; Savettieri, G.; Tedeschi, G.
In: Neurological Sciences, Vol. 32, No. 2, 04.2011, p. 351-358.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Natalizumab therapy of multiple sclerosis
T2 - Recommendations of the Multiple Sclerosis Study Group-Italian Neurological Society
AU - Ghezzi, A.
AU - Grimaldi, L. M E
AU - Marrosu, M. G.
AU - Pozzilli, C.
AU - Comi, G.
AU - Bertolotto, A.
AU - Trojano, M.
AU - Gallo, P.
AU - Capra, R.
AU - Centonze, D.
AU - Millefiorini, E.
AU - Sotgiu, S.
AU - Brescia Morra, V.
AU - Amato, M. P.
AU - Lugaresi, A.
AU - Mancardi, G.
AU - Caputo, D.
AU - Montanari, E.
AU - Provinciali, L.
AU - Durelli, L.
AU - Bergamaschi, R.
AU - Bellantonio, P.
AU - Tola, M. R.
AU - Cottone, S.
AU - Savettieri, G.
AU - Tedeschi, G.
PY - 2011/4
Y1 - 2011/4
N2 - Three years after the introduction of natalizumab (NA) therapy for the second line treatment of relapsing-remitting multiple sclerosis (MS), Italian MS centers critically reviewed the scientific literature and their own clinical experience. Natalizumab was shown to be highly efficaciuos in the treatment of MS. However, the risk of progressive multifocal leukoencephalopathy was confirmed and defined better. This article summarizes the MS-SIN Study Group recommendations on the use of NA in MS, with particular reference to the appropriate selection and monitoring of patients as well as to the management of adverse events.
AB - Three years after the introduction of natalizumab (NA) therapy for the second line treatment of relapsing-remitting multiple sclerosis (MS), Italian MS centers critically reviewed the scientific literature and their own clinical experience. Natalizumab was shown to be highly efficaciuos in the treatment of MS. However, the risk of progressive multifocal leukoencephalopathy was confirmed and defined better. This article summarizes the MS-SIN Study Group recommendations on the use of NA in MS, with particular reference to the appropriate selection and monitoring of patients as well as to the management of adverse events.
KW - IRIS
KW - Multiple sclerosis
KW - Natalizumab
KW - PML
UR - http://www.scopus.com/inward/record.url?scp=79952902537&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79952902537&partnerID=8YFLogxK
U2 - 10.1007/s10072-010-0469-0
DO - 10.1007/s10072-010-0469-0
M3 - Article
C2 - 21234775
AN - SCOPUS:79952902537
VL - 32
SP - 351
EP - 358
JO - Neurological Sciences
JF - Neurological Sciences
SN - 1590-1874
IS - 2
ER -